Posted by Michael Wonder on 13 Dec 2022
PharmaJet Partner Immunomic Therapeutics receives FDA fast track designation for pDNA vaccine for skin cancer
13 December 2022 - Vaccine exclusively delivered with the PharmaJet Stratis needle-free injection system.
PharmaJet today announced that their partner Immunomic Therapeutics received FDA fast track designation for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma, a rare but aggressive form of skin cancer.
